Drugs / NC-6004
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02817113 | Jun 2016 → Sep 2018 | head and neck neoplasm | Orient Europharma Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02240238 | May 2014 → May 2019 | cancer | NanoCarrier Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03771820 | Jul 2019 → Apr 2021 | head and neck squamous cell carcinoma | NanoCarrier Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02043288 | Jan 2014 → Dec 2019 | malignant pancreatic neoplasm | Orient Europharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC-6004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02240238 ↗ |
| Modality | Other / unclassified | “NC-6004 is a polymeric micelle containing cisplatin as an active moiety.” NCT02817113 ↗ |
| Route | Intravenous | “NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1” NCT02043288 ↗ |